Transradial access tied to lower all-cause mortality and bleeding than transfemoral access: RTC analysis
Transradial access is associated with lower all-cause mortality and major bleeding at 30 days, compared with transfemoral access for coronary interventions. Radial access bests femoral access not only for reduced bleeding, but mortality as well for coronary angiography with or without percutaneous coronary intervention (PCI), according to a meta-analysis by the Radial...
Transradial access is associated with lower all-cause mortality and major bleeding at 30 days, compared with transfemoral access for coronary interventions. Radial access bests femoral access not only for reduced bleeding, but mortality as well for coronary angiography with or without percutaneous coronary intervention (PCI), according to a meta-analysis by the Radial Trialists' Collaboration.
That's the finding of late breaking research presented in a Hot Line session today at ESC Congress 2022.
Dr. Giuseppe Gargiulo of Federico II University Hospital, Naples, Italy said: "Thirty years after the first radial access interventional coronary procedure on 14 August 1992, our study provides, for the first time, adequate power and solid evidence from high-quality multicentre randomised trials that the use of radial instead of femoral access is associated with reduced all-cause mortality. The benefit accrues early (i.e. within 10 days) after PCI and is maintained up to 30-day follow-up."
European and American guidelines endorse the preferential use of a transradial approach (TRA) over a transfemoral approach (TFA) in patients requiring coronary catheterisation.2-4 TRA has been associated with a lower incidence of access site-related bleeding and vascular complications compared with TFA.
In some studies, but not others, TRA was associated with a mortality benefit; however, none of the analyses were adequately powered for individual endpoints including mortality.6,7 Aggregate-data meta-analyses have been conducted but lack granularity to adjust for confounders or identify subgroups that may particularly benefit or be harmed.
This was the first large individual patient-level data meta-analysis of high-quality multicentre randomised clinical trials to investigate the impact of radial versus femoral artery access for coronary angiography or PCI on mortality and major bleeding.8 Investigators from the Radial Trialists' Collaboration (RTC) obtained individual patient data from trials comparing TRA versus TFA among participants undergoing coronary angiography with or without PCI.
The meta-analysis included pooled data from seven trials with a total of 21,600 patients, of which 10,775 were randomised to TRA and 10,825 were randomised to TFA. The median age of participants was 63.9 years, 31.9% were women, 95% presented with acute coronary syndrome, and 75.2% underwent PCI.
The primary outcome was all-cause mortality at 30 days and the co-primary outcome was major bleeding at 30 days. The primary analysis was conducted based on the intention-to-treat cohort. The incidence of all-cause death was 1.6% in the TRA group and 2.1% in the TFA group, for a hazard ratio of 0.77 (95% confidence interval [CI] 0.63–0.95; p=0.012). Major bleeding was also significantly reduced with TRA versus TFA, occurring at rates of 1.5% and 2.7%, respectively, for an odds ratio of 0.55 (95% CI 0.45–0.67; p<0.001).
The survival benefit was confirmed in the per-protocol, as-treated, PCI, acute coronary syndrome, and myocardial infarction cohorts. The effects of TRA were also consistent across the majority of pre-specified subgroups, and the findings indicated that patients with baseline anaemia might have a greater mortality benefit compared to those without anaemia.
In a multivariable model, TRA was independently associated with a significant 24% relative risk reduction of 30-day all-cause mortality and 51% reduction of major bleeding. Mediation analysis showed that the benefit of TRA on mortality was only marginally driven by the prevention of major bleeding.
Dr. Gargiulo said: "Our study conclusively indicates a favourable prognostic impact of TRA over TFA in terms of survival. It should be noted that the advantages of TRA for mortality, major bleeding and other clinical outcomes primarily apply to acute coronary syndrome patients, who represented approximately 95% of our study population, and cannot be fully extended to elective patients undergoing coronary angiography with or without PCI."
He concluded: "This analysis provides definitive evidence that TRA should be considered the gold standard for patients undergoing cardiac catheterisation with or without PCI, supporting the 'radial-first' approach."
1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119-177.
2. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42:1289-1367.
3. Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79:e21–e129.
4. Valgimigli M, Saia F, Guastaroba P, et al. Transradial versus transfemoral intervention for acute myocardial infarction: a propensity score-adjusted and -matched analysis from the REAL (REgistro regionale AngiopLastiche dell'Emilia-Romagna) multicenter registry. JACC Cardiovasc Interv. 2012;5:23–35.
5. Valgimigli M, Gagnor A, Calabro P, et al. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385:2465-2476.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Before Joining Medical Dialogues, he has served at important positions in the medical industry in India including as the Hony. Secretary of the Delhi Medical Association as well as the chairman of Anti-Quackery Committee in Delhi and worked with other Medical Councils in India. Email: email@example.com. Contact no. 011-43720751